What happens subsequently in AML when cytogenetic abnormalities persist at bone marrow harvest? Results of the 10th UK MRC AML trial. Medical Research Council Leukaemia Working Parties

Bone Marrow Transplantation
D GrimwadeA Goldstone

Abstract

Cytogenetic analysis performed at diagnosis is widely recognised to provide one of the most valuable prognostic indicators in AML. Yet any role for this technique in residual disease assessment, particularly in the context of subsequent transplantation procedures has been incompletely explored. The present study considers the outcome of 190 patients drawn from the UK MRC AML 10 trial in whom cytogenetics were assessed whilst in morphological CR at the time of bone marrow harvest. Cytogenetics at this stage were abnormal in 19 patients (10%). In 11/19 patients, the abnormalities detected reflected the acquisition of new clonal (3/11) or nonclonal changes (8/11) that were not identified at diagnosis; comparison of this group to patients with normal cytogenetics at harvest provided no evidence that such acquired changes are of prognostic significance. In 8/19 patients, abnormalities detected were indicative of persistence of the disease-related clone in harvested marrow. Two of these patients died of sepsis during consolidation therapy. Two received ABMT in first morphological CR: one patient with AML associated with a favourable karyotype (+8,inv(16)) remains in CR, 5.5 years post-transplant, whereas the other with cytogenetic ab...Continue Reading

Citations

Aug 25, 2001·Cancer Genetics and Cytogenetics·W EmbergerK Wagner
Apr 18, 2003·Cancer Genetics and Cytogenetics·Daniel L Van Dyke, Anne Wiktor
Dec 26, 2006·International Journal of Hematology·Nobuaki DobashiNoriko Usui
May 10, 2002·Leukemia & Lymphoma·Tadeusz Robak, Agata Wrzesień-Kuś
May 4, 2002·Best Practice & Research. Clinical Haematology·David Grimwade
Sep 18, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Betul OranMarcos de Lima
Aug 11, 2012·Blood·Ursula CreutzigUNKNOWN AML Committee of the International BFM Study Group
Oct 20, 2001·Best Practice & Research. Clinical Haematology·D Grimwade
Jul 6, 2005·Cell Biology International·Alwin KrämerAnthony D Ho
May 6, 2008·Blood Reviews·Tom Lodewyck, Jan J Cornelissen
Dec 13, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Andrew D ChantryUNKNOWN BSBMT Clinical Trials Committee
Sep 15, 2010·Best Practice & Research. Clinical Haematology·William ArceseUNKNOWN Rome Transplant Network
May 29, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Philippe ArmandRobert J Soiffer
Dec 6, 2011·Leukemia Research·Sanjeev Kumar SharmaRenu Saxena
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciClara D Bloomfield
Nov 10, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sherif S FaragClara D Bloomfield
Jun 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter PaschkaClara D Bloomfield
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Jan 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefan FröhlingKonstanze Döhner
Nov 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciClara D Bloomfield
Aug 4, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R F SchlenkG Heil
Aug 13, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dimitri A BreemsBob Löwenberg
Jan 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dimitri A BreemsBob Löwenberg
Aug 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter PaschkaUNKNOWN Cancer and Leukemia Group B
Jun 18, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yves PerelUNKNOWN Group LAME of the French Society of Pediatric Hematology and Immunology
Dec 4, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jürgen KrauterGerhard Heil
Apr 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hélène LapillonneJudith Landman-Parker
Sep 13, 2005·Oncogene·Ralph GrassmannKuan-Teh Jeang
May 29, 2002·Oncogene·Joseph M ScanduraStephen D Nimer
May 29, 2002·Oncogene·Shinichi KitadaJohn C Reed

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.